Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4785561
Max Phase: Preclinical
Molecular Formula: C125H195IN34O30
Molecular Weight: 2781.05
Molecule Type: Unknown
Associated Items:
ID: ALA4785561
Max Phase: Preclinical
Molecular Formula: C125H195IN34O30
Molecular Weight: 2781.05
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](Cc2ccc(I)cc2)C(=O)N2CCC[C@H]2C(=O)N[C@H](Cc2ccc(-c3ccccc3)cc2)C(=O)O)C[C@@H]2CCCC[C@@H]21)N(C)C(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCCNC(=N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CCCNC(=N)N)NC(=O)[C@H](CCCCNC(=N)N)NC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC[C@H](NC(=O)CCCCCCCCC(=O)O)C(=O)O
Standard InChI: InChI=1S/C125H195IN34O30/c1-76(2)65-98(115(178)156-94(72-161)112(175)153-91(69-83-70-137-75-145-83)111(174)148-84(28-15-18-50-127)107(170)144-71-105(167)160-95-33-14-13-27-81(95)68-99(160)116(179)154-92(66-78-40-44-82(126)45-41-78)119(182)159-58-24-35-97(159)114(177)155-93(121(185)186)67-77-38-42-80(43-39-77)79-25-9-8-10-26-79)157(3)117(180)88(32-22-54-143-125(135)136)152-113(176)96-34-23-57-158(96)118(181)89(30-17-20-52-141-123(131)132)151-110(173)87(46-48-100(128)162)150-109(172)86(31-21-53-142-124(133)134)149-108(171)85(29-16-19-51-140-122(129)130)146-104(166)74-190-64-62-188-60-56-139-103(165)73-189-63-61-187-59-55-138-101(163)49-47-90(120(183)184)147-102(164)36-11-6-4-5-7-12-37-106(168)169/h8-10,25-26,38-45,70,75-76,81,84-99,161H,4-7,11-24,27-37,46-69,71-74,127H2,1-3H3,(H2,128,162)(H,137,145)(H,138,163)(H,139,165)(H,144,170)(H,146,166)(H,147,164)(H,148,174)(H,149,171)(H,150,172)(H,151,173)(H,152,176)(H,153,175)(H,154,179)(H,155,177)(H,156,178)(H,168,169)(H,183,184)(H,185,186)(H4,129,130,140)(H4,131,132,141)(H4,133,134,142)(H4,135,136,143)/t81-,84-,85-,86+,87-,88+,89-,90-,91-,92-,93+,94-,95-,96-,97-,98-,99-/m0/s1
Standard InChI Key: DWYNNXITSWEIIQ-GYFSBXTESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 2781.05 | Molecular Weight (Monoisotopic): 2779.3823 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Reed AB,Lanman BA,Holder JR,Yang BH,Ma J,Humphreys SC,Wang Z,Chan JCY,Miranda LP,Swaminath G,Allen JG. (2020) Half-life extension of peptidic APJ agonists by N-terminal lipid conjugation., 30 (21.0): [PMID:32858124] [10.1016/j.bmcl.2020.127499] |
Source(1):